Thousands of dementia patients will be included in accelerated clinical trials for new drugs, in a significant development that aims to accelerate research and find more effective treatments.
The scheme, worth around £20 million, is expected to significantly expand participation in cutting-edge scientific studies and shorten the time to testing new therapies.
Over 15,500 people aged 65 to 75 have been invited to become part of the Dementia Trials Accelerator programme, which connects leading researchers with suitable volunteers in the UK.
Currently, recruiting participants for a dementia study can take up to three years, while cancer studies take an average of 2.3 years to complete, including the recruitment phase. Experts say the chronic lack of participants is one of the main obstacles to advancing dementia research.
The latest figures show that during 2024–2025, only 173 patients in England were included in advanced trials of dementia drugs – far fewer compared to other diseases such as stroke, heart disease or cancer.
There is currently no cure for dementia and existing treatments have shown limited results in slowing it down. The disease claims around 76,000 lives each year and is considered the leading cause of death in the UK.
The new initiative aims to raise awareness, improve early diagnosis, promote scientific research and improve patient care.
The Dementia Trials Accelerator program represents a major step towards these objectives, bringing together patients, universities, research institutes and the private sector in a broad collaboration.
Initial participants have already begun testing at clinics, where they undergo cognitive assessments, blood tests, and basic measurements such as weight, height, and blood pressure. The blood samples are analyzed for biomarkers associated with the risk of developing dementia.
In the first few weeks alone, over 800 people have been involved in this program. By early 2027, it is aimed that over 10,000 participants will be ready for future studies.
One of the participants, 75-year-old Susie, said that personal experience had prompted her to get involved: her mother suffered from Alzheimer's and her deterioration without a cure was painful for the whole family. She emphasizes that even as a retired doctor she has seen firsthand the challenges this disease brings and believes that participating in research is essential.
Experts stress that any major breakthrough in dementia treatment will come through clinical trials. This initiative is seen as a real opportunity to accelerate the discovery of new treatments, improve early diagnosis and change the lives of patients in the future. /GazetaExpress/
t7 live
